Advancing our understanding of complex diseases starts with fundamental biology. We’re sharing a new publication from Frontiers in Immunology that summarizes evolving insights into the underlying biology of lupus, highlighting the role of immune cell dynamics and interferon-driven inflammation across systemic and cutaneous diseases. The research underscores the complexity and heterogeneity of lupus—and reflects our long-term commitment to advancing science to inform future innovations in this disease area. Read the publication: https://bit.ly/4vPf9XF
About us
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities, to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth. With approximately 7,000 people worldwide, we are truly a global organization, headquartered in Cambridge, Massachusetts, which is also home to our research operations. Our international headquarters are based in Baar, Switzerland and we have world-class manufacturing facilities in North Carolina and Solothurn, Switzerland. We offer therapies globally through direct affiliate presence in 30 countries and a network of distribution partners in over 50 additional countries. For more information, please visit www.biogen.com. Community Guidelines: https://www.biogen.com/community-guidelines.html Follow us on social media – LinkedIn, Instagram, Facebook, X, and YouTube.
- Website
-
http://www.biogen.com
External link for Biogen
- Industry
- Biotechnology Research
- Company size
- 5,001-10,000 employees
- Headquarters
- Cambridge, MA
- Type
- Public Company
Locations
-
Primary
Get directions
225 Binney Street
Cambridge, MA 02142, US
-
Get directions
Landis & Gyr-Strasse 3
Zug, CH 6300, CH
-
Get directions
P.O. Box 14627
5000 Davis Drive
Research Triangle Park, NC 27709, US
Employees at Biogen
Updates
-
Our colleagues are getting ready to knock it out of the (Research Triangle) Park! Our NC team will join the Durham Bulls Baseball Club to celebrate the U.S. 250th with our community. Each game this week will showcase some of the people and partnerships that make Research Triangle Park an all-star community. We are so excited to have members of #TeamBiogen step up to the plate to be a part of these celebrations. Go Bulls! Included in video: Alex Cameron, Alex Murray, Jimmy Smith, Armond Shaw, Mike Birling, Chris Florek, Jared Sanders, MBA, PMP, Nick Bavin
-
Today, we announced we’re attending the Alzheimer's Association® International Conference (AAIC) to share new data from our Alzheimer’s disease portfolio—including initial data from the Phase 2 study of our investigational tau-targeting therapy. Learn more about our upcoming presentations at #AAIC26: https://lnkd.in/eUkfHVnP #News
-
At the European Academy of Neurology (EAN) Congress, our symposium will bring together experts to discuss how clinical evidence can help inform everyday care for individuals living with Friedreich ataxia, with a focus on practical approaches and the evolving evidence landscape. Join the conversation at #EAN2026!
-
-
A kidney transplant is life-changing, but challenges can remain—some people may face antibody-mediated rejection (AMR), shifting focus from receiving a kidney to keeping it from failing. This year, we supported the Transplant Life Foundation's Transplant Games of America to raise awareness and advocate for more options for people living with a kidney transplant. Learn about our work in kidney disease, including AMR: https://ow.ly/L6kL50Zhgna
-
-
We’re proud to be part of Massachusetts’ biotechnology legacy and the vibrant ecosystem that continues to make Kendall Square a leader in innovation. As a company founded in Cambridge decades ago, we have seen firsthand how collaboration, scientific excellence, and a shared commitment to patients can turn bold ideas into meaningful progress.
Fifty years ago today, a public hearing in the Cambridge City Council chambers helped launch an industry, right here in Massachusetts. Mayor Al Vellucci convened it to challenge the safety of recombinant DNA research. The process he set off produced something that outlasted the politics: clear local rules and public trust. That certainty is what let companies build here. Phil Sharp has said those settled guidelines are the reason Biogen chose Cambridge. Five decades later, this square mile of Massachusetts is still the center of gravity for biotech, and the industry has expanded well beyond Kendall Square. The science, the talent, the capital, and the care are all here, turning ideas into cures. Listen to the pioneers who built it tell that story. This is the place.
-
We're at the Cure SMA 2026 Annual SMA Conference this week, joining the advocates, clinicians, and families helping to shape the future of spinal muscular atrophy (SMA) care. Kenneth Hobby, President of Cure SMA, shares how scientific progress and advocacy have changed expectations for people living with SMA over the past decade. Learn more about our work in SMA: https://lnkd.in/gqq2A5_b
-
We‘re proud to recognize our colleagues Mark LoPresti, Sarah Coffee, and Aaron Fischer as finalists for the 2026 Manufacturing Leadership Awards. Being named a finalist by the National Association of Manufacturers - NAM is a meaningful acknowledgment of their leadership, innovation, and impact across manufacturing operations. Their work supports the reliable delivery of medicines for patients today while strengthening our capabilities to help advance Biogen’s pipeline and potential future launches. Congratulations on this well-deserved recognition! #ManufacturingLeadership | #TeamBiogen
-
-
We’re pleased to join the European Academy of Neurology (EAN) Congress 2026 in Geneva, Switzerland. Our team will host a talk on the burden of Friedreich ataxia (FA), exploring patient perspectives on symptoms, daily life impact and healthcare challenges. Stop by booth E14 to learn more. #EAN2026 | #FriedreichAtaxia
-
-
From breakthrough science to meaningful conversations, our Chief Medical Officer, Daniel Quirk, MD, MPH, MBA, takes you on the grounds of #ATCBoston2026, where we shared data on our investigational therapy designed to target CD-38 cells in antibody-mediated rejection (AMR) and microvascular inflammation (MVI) and research in rare complement-driven kidney disease. Learn about our advancements in immune-mediated kidney disease: https://lnkd.in/g59BwFgq